Cholestatic Pruritus Market Report 2026

The cholestatic pruritus market size has grown strongly in recent years. It will grow from $20.22 billion in 2025 to $21.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, limited effectiveness of traditional antihistamines, growth of hepatology specialty care, rising diagnosis of cholestatic disorders, expansion of supportive care treatments.

The cholestatic pruritus market size is expected to see strong growth in the next few years. It will grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing approval of novel therapeutics, rising focus on quality-of-life improvement, expansion of targeted liver disease drugs, growing investment in rare disease research, increasing adoption of personalized treatment plans. Major trends in the forecast period include increasing development of targeted anti-pruritic therapies, rising focus on symptom-specific treatment approaches, growing use of oral bile acid modulators, expansion of research in liver disease management, enhanced patient-centered care strategies.

The rising prevalence of liver diseases is expected to drive growth in the cholestatic pruritus market in the coming years. Liver diseases encompass a wide range of conditions affecting liver function, including infections, autoimmune disorders, genetic disorders, and toxin-induced damage, which can lead to inflammation, scarring, or liver failure. Factors such as obesity, diabetes, alcohol use, viral hepatitis, and exposure to environmental toxins are contributing to the increasing prevalence of liver disease. Cholestatic pruritus serves as a key symptom indicating impaired bile flow, helping to identify and manage underlying hepatic conditions. For example, in 2023, the Office for Health Improvement and Disparities (OHID), a UK-based government agency, reported 85,665 hospital admissions for liver disease in England during the financial year. Consequently, the growing prevalence of liver diseases is driving the cholestatic pruritus market.

Key companies in the cholestatic pruritus market are developing innovative oral solutions to manage symptoms more effectively, improve patient compliance, and provide targeted relief by addressing bile acid accumulation and inflammation. Oral solutions for cholestatic pruritus are liquid formulations designed to reduce bile acid buildup and alleviate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, received FDA approval for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC). This once-daily ileal bile acid transporter inhibitor holds breakthrough therapy designation for PFIC type 2 and offers a critical treatment option for patients with rare subtypes of cholestatic pruritus.

In September 2023, Travere Therapeutics Inc., a US-based biopharmaceutical company, partnered with Mirum Pharmaceuticals Inc. Through this partnership, Travere focuses on its core therapeutic areas while enabling Mirum to expand its portfolio and advance the development and commercialization of bile acid therapies for rare liver diseases, including those leading to cholestatic pruritus. Mirum Pharmaceuticals is a US-based company specializing in therapies for rare liver conditions.

Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, ProQR Therapeutics NV.

North America was the largest region in the cholestatic pruritus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cholestatic pruritus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cholestatic pruritus market by increasing costs of imported active pharmaceutical ingredients, specialty medications, and diagnostic tools used in liver disease management. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported drugs and formulations, while Asia-Pacific faces higher manufacturing costs for specialty treatments. These tariffs are contributing to higher therapy prices and access challenges. However, they are also encouraging domestic drug manufacturing, regional sourcing of APIs, and increased investment in locally produced therapies to improve long-term supply stability.

The cholestatic pruritus market research report is one of a series of new reports that provides cholestatic pruritus market statistics, including cholestatic pruritus industry global market size, regional shares, competitors with a cholestatic pruritus market share, detailed cholestatic pruritus market segments, market trends and opportunities, and any further data you may need to thrive in the cholestatic pruritus industry. This cholestatic pruritus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cholestatic pruritus is severe itching caused by the accumulation of bile acids in the skin, typically resulting from liver diseases that impair bile flow. This condition can significantly impact a patient’s quality of life and often requires targeted treatment to relieve symptoms and address the underlying liver dysfunction.

The main disease types associated with cholestatic pruritus include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and other related conditions. PBC is a chronic autoimmune liver disease that progressively damages the bile ducts, leading to bile accumulation, liver injury, and potential cirrhosis. Treatment options for cholestatic pruritus include medications, phototherapy, and other therapies, administered via oral, topical, or injectable routes. The primary end users of these treatments are hospitals, clinics, ambulatory care centers, and homecare providers.

The cholestatic pruritus market consists of revenues earned by entities by providing services such as diagnosis and screening services, medical consultations and treatment management, patient support programs, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholestatic pruritus market also includes sales of ursodeoxycholic acid, topical corticosteroids, and opioid antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.